Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs

Abstract

This study utilizes both public and private data sources to estimate clinical phase transition and clinical approval probabilities for drugs in the development pipelines of the 50 largest pharmaceutical firms (by sales). The study examined the development histories of these investigational compounds from the time point at which they first entered clinical testing (1993-2004) through June 2009. The clinical approval success rate in the United States was 16% for self-originated drugs (originating from the pharmaceutical company itself) during both the 1993-1998 and the 1999-2004 subperiods. For all compounds (including licensed-in and licensed-out drugs in addition to self-originated drugs), the clinical approval success rate for the entire study period was 19%. The estimated clinical approval success rates and phase transition probabilities differed significantly by therapeutic class. The estimated clinical approval success rate for self-originated compounds over the entire study period was 32% for large molecules and 13% for small molecules. The estimated transition probabilities were also higher for all clinical phases with respect to large molecules.

The High Cost of Cancer Drugs and What We Can Do About It

“…In addition, only 16% to 19% of products that enter clinical trials successfully make it to market on completion of the clinical testing and approval process. 10,12 To their credit, pharmaceutical companies are exploring ways to decrease drug development costs by using contract research organizations and contract manufacturing organizations. The retail prices of drugs are a function of the costs of development, the addressable patient population, the patent life, and the projected returns on investment.…”

Repurposing Drugs in the Genomics Era: Bioinformatics Approaches

“…1 In recent years discovering new uses for already approved drugs is becoming increasingly attractive. [2][3][4][5] This approach, termed as "drug repurposing" offers several advantages.…”

A Decade of Cell Therapy Clinical Trials (2000–2010)

“…For example, from historical data, the attrition rates for potential new drugs moving from one phase to the next is known, and thus forecasts for pharmaceuticals and biotechnology can be deduced [4,5]. The CTI is fortunate that it can now boast several products that are achieving significant reimbursement, including its first blockbuster product, Dendreon's Provenge ® [6], reimbursed at US$93,000 per patient.…”